Exit Options for John Hancock Bond and Corporate Finance Group: Hanover Communications In... - 28 Strategic Investors

View x

Takeda Completes Sale of Select OTC and Non-Core Assets to Acino

Takeda Pharmaceutical Company Limited completed its previously-announced sale of a portfolio of select over-the-counter and prescription pharmaceutical assets in a number of Near East, Middle East and Africa countries within its Growth and Emerging Markets Business Unit to Acino for a total value in excess of $200 million USD. The divestment agreement was first announced in October 2019. Takeda intends to use proceeds from these divestitures to reduce debt and continue to deleverage towards its target of 2x net debt/adjusted EBITDA within March 2022 - March 2024. Takeda remains committed to rapid deleveraging driven by strong cash flow and divestiture proceeds, while also simplifying its portfolio.